Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 200...(discontinuance of the Company's embolic ...),Health

Date:6/23/2008

discontinuance of the Company's embolic protection platform of $3.1 million, or $0.25 per share. Including these items, the 2008 fourth quarter loss per share is expected to be in a range of ($0.08) to ($0.09) compared to a loss of ($0.15) per share for the same period in fiscal year 2007.

Fiscal Year 2008

Fiscal year 2008 net biomaterials sales guidance was previously announced in a range of $46.9 to $47.1 million. The Company is now estimating biomaterials product sales of $47.2 to $47.4 million, an increase of 15% over the prior year, and total net sales, including endovascular products, in the range of $53.2 to $53.4 million, an 18% increase from fiscal year 2007. Fiscal year 2008 royalties are estimated to be $25.7 to $25.8 million, representing 5% growth from fiscal year 2007. Total revenues are expected to be in a range of $78.9 to $79.2 million, a 13% increase from the prior fiscal year.

Fiscal year 2008 adjusted diluted earnings per share* are expected to be in the range of $0.96 to $0.97, representing an increase of 81% to 83% compared to fiscal year 2007. Estimated adjusted diluted earnings per share for fiscal year 2008 exclude after-tax charges of $7.3 million, or $0.58 per share, for the acceleration of stock awards, discontinuation of the Company's embolic protection platform, and sale of the Company's endovascular business. Adjusted diluted earnings per share for the fiscal year 2007 of $0.53 excluded an after-tax charge for the discontinuance of the Company's embolic protection platform of $3.1 million, or $0.25 per share. Including these items, reported diluted earnings per share for fiscal 2008 are expected to be in a range of $0.38 to $0.39, representing a 31% to 34% increase compared to fiscal year 2007 reported diluted earnings per share of $0.29.

"We are completing our fiscal year with another strong quarter," commented Joe Kaufmann, President and CEO. "Our Biomaterials business, notably the orthopaedic segment, con
'/>"/>

SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. Kensey Nash Reports Third Quarter Record Revenue and Sales
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference